Phreesia (NYSE:PHR) Price Target Lowered to $30.00 at Robert W. Baird

Phreesia (NYSE:PHR) had its price objective reduced by analysts at Robert W. Baird from $34.00 to $30.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Robert W. Baird’s price objective would indicate a potential upside of 22.20% from the stock’s current price.

Several other analysts have also issued reports on PHR. Truist Financial upped their price target on shares of Phreesia from $29.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, September 6th. Needham & Company LLC reissued a “buy” rating and issued a $29.00 price objective on shares of Phreesia in a research report on Tuesday. JPMorgan Chase & Co. increased their price objective on shares of Phreesia from $27.00 to $28.00 and gave the company an “overweight” rating in a research report on Monday, September 9th. DA Davidson restated a “buy” rating and issued a $32.00 price target on shares of Phreesia in a research note on Thursday, September 5th. Finally, JMP Securities restated a “market outperform” rating and issued a $30.00 price target on shares of Phreesia in a research note on Tuesday. One analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, Phreesia has an average rating of “Moderate Buy” and a consensus target price of $29.33.

Phreesia Stock Performance

NYSE PHR opened at $24.55 on Wednesday. The company has a current ratio of 1.74, a quick ratio of 1.77 and a debt-to-equity ratio of 0.04. The firm’s fifty day moving average price is $20.34 and its two-hundred day moving average price is $21.78. Phreesia has a 1 year low of $17.07 and a 1 year high of $29.16. The firm has a market capitalization of $1.43 billion, a P/E ratio of -16.70 and a beta of 0.98.

Phreesia (NYSE:PHR) last posted its quarterly earnings results on Monday, December 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.04. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The firm had revenue of $106.80 million for the quarter, compared to analyst estimates of $106.33 million. During the same period in the prior year, the firm posted ($0.58) earnings per share. The company’s quarterly revenue was up 16.6% compared to the same quarter last year. As a group, research analysts anticipate that Phreesia will post -1.22 EPS for the current year.

Insiders Place Their Bets

In other news, SVP Amy Beth Vanduyn sold 25,447 shares of the stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $20.93, for a total value of $532,605.71. Following the completion of the transaction, the senior vice president now owns 93,470 shares of the company’s stock, valued at approximately $1,956,327.10. This represents a 21.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Allison C. Hoffman sold 1,212 shares of the stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $21.03, for a total transaction of $25,488.36. Following the completion of the transaction, the general counsel now directly owns 119,791 shares of the company’s stock, valued at $2,519,204.73. This trade represents a 1.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 53,569 shares of company stock worth $1,123,014 over the last ninety days. Corporate insiders own 5.80% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. International Assets Investment Management LLC raised its holdings in Phreesia by 2,179.7% in the 3rd quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock valued at $33,000 after buying an additional 1,395 shares during the last quarter. nVerses Capital LLC raised its holdings in Phreesia by 76.5% in the 2nd quarter. nVerses Capital LLC now owns 3,000 shares of the company’s stock valued at $64,000 after buying an additional 1,300 shares during the last quarter. Lombard Odier Asset Management USA Corp bought a new position in Phreesia in the 2nd quarter valued at approximately $202,000. Point72 DIFC Ltd bought a new position in Phreesia in the 2nd quarter valued at approximately $209,000. Finally, XTX Topco Ltd bought a new position in Phreesia during the 3rd quarter worth approximately $247,000. Institutional investors own 92.10% of the company’s stock.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.